By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.




CEO: Richard A. Gonzalez

CFO: William J. Chase


Please click here for Abbvie job opportunities.


Please click here for clinical trial information..


Key Statistics

Ownership: Public

Web Site: AbbVie
Symbol: ABBV

Company News
AbbVie (ABBV) Presents Pivotal Phase III Data On Investigational Treatment Elagolix At The World Congress On Endometriosis 5/18/2017 6:39:55 AM
AbbVie (ABBV) Release: IMBRUVICA (Ibrutinib) Pooled Outcomes Data From Three Phase III Studies Suggest Potential Clinical Efficacy In Patients With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 5/15/2017 6:26:04 AM
AbbVie (ABBV) Announces Positive Phase II Study Results For Upadacitinib (ABT-494), An Investigational JAK1-Selective Inhibitor, In Crohn's Disease 5/9/2017 9:38:25 AM
5 Things AbbVie (ABBV) Management Just Said That You'll Want to Know 5/4/2017 7:01:37 AM
AbbVie (ABBV) Reports First-Quarter 2017 Financial Results 4/27/2017 11:57:50 AM
AbbVie (ABBV) Reports First-Quarter 2017 Financial Results 4/27/2017 11:17:49 AM
AbbVie (ABBV), Pfizer (PFE) Get in On Alzheimer's Pharma Aquinnah's $10 Million Funding Round 4/25/2017 6:35:27 AM
AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate In Chronic Hepatitis C Patients With Compensated Cirrhosis 4/20/2017 7:01:32 AM
Enanta Pharmaceuticals, Inc. Announces 99 Percent SVR12 Rate In Chronic HCV Patients With Compensated Cirrhosis Treated With AbbVie (ABBV)'s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) 4/20/2017 6:06:50 AM
AbbVie (ABBV)'s PARP Inhibitor Fails to Deliver in Two Late-Stage Studies 4/20/2017 5:43:03 AM